利用治疗药物监测表征头孢吡肟相关神经毒性
CRN发生率为4.4%(22/503),CRN组平均谷浓度显著高于非CRN组(61.8±33.7 vs 30±27.7 mg/L,p=0.0002),谷浓度和肾功能不全是CRN的独立危险因素。
要点
- CRN发生率为4.4%,肾功能不全患者风险更高。
- CRN组头孢吡肟平均谷浓度显著高于非CRN组。
- 初始用药72小时后延迟TDM与CRN风险增加3倍相关。
核心结论
- 肾功能不全住院患者应谨慎使用头孢吡肟,因存在神经毒性风险。
- 早期利用TDM优化剂量可能减少不良反应并提高患者安全。
研究设计与样本
- 采用标准定义识别潜在CRN病例,利用贝叶斯后验法计算每日平均AUC,并进行多元回归分析。
主要发现
- CRN发生率为4.4%(22/503)。
- CRN组平均谷浓度显著高于非CRN组(61.8±33.7 vs 30±27.7 mg/L,p=0.0002)。
- CRN组肾功能不全、高血压和糖尿病发生率高于非CRN组。
- 谷浓度和肾功能不全是CRN的独立危险因素。
- CRN最常见EEG模式为背景节律中度广泛性减慢。
关键数值与推荐
- CRN组平均谷浓度61.8±33.7 mg/L,非CRN组30±27.7 mg/L(p=0.0002)。
- 初始用药72小时后延迟TDM与CRN风险增加3倍相关。
临床怎么用
- 对肾功能不全患者使用头孢吡肟时应警惕神经毒性。
- 建议早期进行TDM以优化头孢吡肟剂量,减少不良反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY OBJECTIVES: Data evaluating cefepime thresholds associated with neurotoxicity remain limited. The objectives of this study were to evaluate the incidence of cefepime-related neurotoxicity (CRN) in patients with plasma cefepime concentrations, assess the relationship between cefepime exposure and CRN, investigate clinical factors associated with CRN, and describe electroencephalogram (EEG) abnormalities in CRN. DESIGN: This was a retrospective study of adult inpatients admitted between 2016 and 2018 who received cefepime therapeutic drug monitoring (TDM). Potential CRN cases were identified utilizing a standard definition. The primary outcomes of the study were to determine the incidence of CRN and evaluate the relationship between cefepime trough concentrations, the average daily AUC, and neurotoxicity. Bayesian posteriors were generated for each patient using a cefepime pharmacokinetic (PK) model, and the mean daily area under the concentration-time curve (AUC) was calculated. Multiple regression was performed to assess the association between CRN, cefepime PK, and clinical predictors of neurotoxicity. MAIN RESULTS: Four hundred eighty-one patients with 503 hospital encounters received cefepime TDM and were included in the analysis. The incidence of CRN was 4.4% (22/503). Patients with CRN had a higher incidence of renal dysfunction, hypertension, and diabetes mellitus compared to patients without CRN (non-NT). The mean cefepime trough concentration was significantly greater in the CRN patients than in the non-NT group (61.8 ± 33.7 vs. 30 ± 27.7 mg/L, respectively, p = 0.0002). Cefepime trough concentration and renal dysfunction were independently associated with increased risk of CRN in the adjusted multiple regression model. Moderate generalized slowing of the background rhythm was the most common EEG pattern associated with CRN. Delaying cefepime TDM greater than 72 h after the initiation of cefepime was associated with a 3-fold increased risk of CRN. CONCLUSION: Cefepime should be used cautiously in hospitalized patients with renal dysfunction due to the risk of neurotoxicity. Dose optimization utilizing TDM early in cefepime treatment may minimize adverse effects and improve patient safety.
引用
- Venugopalan V, Casaus D, Kainz L, et al. Use of therapeutic drug monitoring to characterize cefepime-related neurotoxicity. Pharmacotherapy. 2022. PMID: 36401796. doi:10.1002/phar.2744
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。